Story perspectives

Pro-Life Advocates Demand Accountability Over Mifepristone Safety Risks

11/2/2025

Summary

Story summary

Pro-Life in the Public Square (PLPS) criticizes the FDA's handling of mifepristone.
Critics argue that relaxing safety measures for mifepristone endangered women's health.
Mark Wiltz of Live Action warns that mifepristone is high-risk, with one in twenty-five women requiring emergency care after use.
There are calls for transparency about the reviewers involved in mifepristone's approval, as their identities remain undisclosed.
Lawsuits claim the FDA's actions compromised safety and seek accountability.

History

Historical Context

The FDA approved mifepristone for medical abortions in September 2000, following extensive clinical trials. By 2020, over 1.5 million women had used the drug, which is 97% effective when combined with misoprostol. Ongoing legal challenges reflect historical tensions over reproductive rights and drug safety, echoing past controversies like the thalidomide scandal of the 1960s.

1 of 2

Story summary

Pro-Life in the Public Square (PLPS) criticizes the FDA's handling of mifepristone.
Critics argue that relaxing safety measures for mifepristone endangered women's health.
Mark Wiltz of Live Action warns that mifepristone is high-risk, with one in twenty-five women requiring emergency care after use.
There are calls for transparency about the reviewers involved in mifepristone's approval, as their identities remain undisclosed.
Lawsuits claim the FDA's actions compromised safety and seek accountability.

1 / 2